Angiochem Se Voit Accorder Un Prêt Du Gouvernement Du Québec Afin De Conduire Son Essai Clinique De Phase III
04 juin 2019 07h00 HE
|
Angiochem
MONTRÉAL, 04 juin 2019 (GLOBE NEWSWIRE) -- Angiochem Inc. (“Angiochem”) a annoncé aujourd’hui que le Gouvernement du Québec, par l’entremise du programme BioMed Propulsion, lui a accordé un...
Angiochem Receives Loan from Quebec Government to Perform Phase III Trial
04 juin 2019 07h00 HE
|
Angiochem
MONTREAL, June 04, 2019 (GLOBE NEWSWIRE) -- Angiochem Inc. (“Angiochem”) announced today that it has been granted a $4 million loan from the Quebec Government through its BioMed Propulsion program....
Angiochem Announces Special Protocol Assessment (SPA) with US Food and Drug Administration (FDA)
06 août 2018 07h00 HE
|
Angiochem
MONTREAL, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Angiochem Inc. (“Angiochem”) announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special...
Angiochem receives $7.5 million in Series C financing
01 août 2018 07h00 HE
|
Angiochem
MONTREAL, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Angiochem Inc. (“Angiochem”) announced today that it has secured a $7.5 million Series C financing to pursue its development plan. Angiochem is currently...
Angiochem and Xinogen to Enter License Agreement
03 janv. 2018 10h35 HE
|
Angiochem
HONG KONG, CHINA and MONTREAL, QC--(Marketwired - January 03, 2018) - Angiochem Inc. and Xinogen (Hong Kong) Pharma Co. Ltd. ("Xinogen"), a wholly-owned subsidiary of Beijing Shenogen Pharma Group...
Angiochem to Present at SNO Annual Meeting
14 nov. 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - November 14, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make an...
Angiochem's ANG1005 Shows Clinical Benefits and Prolonged Survival for Breast Cancer Patients With Brain Metastases
17 oct. 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - October 17, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, recently presented data...
Angiochem to Present at EANO 2016 Meeting
11 oct. 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - October 11, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make an...
Angiochem to Present at ESMO 2016 Congress
03 oct. 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - October 03, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make a...
Angiochem Announces Successful End-of-Phase 2 Meeting With FDA for ANG1005
23 juin 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - June 23, 2016) - Angiochem, a biotechnology company developing proprietary peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, today announced...